Trial
NCT01829971
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Mirna Therapeutics, Inc.
Collaborators
Cancer Prevention Research Institute of Texas
Condition
Primary Liver Cancer
Intervention
MRX34
Why stopped
Five immune related serious adverse events
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-09-27